Investigational Drug Information for Treosulfan
✉ Email this page to a colleague
What is the development status for investigational drug Treosulfan?
Treosulfan is an investigational drug.
There have been 43 clinical trials for Treosulfan.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2004.
The most common disease conditions in clinical trials are Leukemia, Myelodysplastic Syndromes, and Preleukemia. The leading clinical trial sponsors are medac GmbH, Fred Hutchinson Cancer Research Center, and National Cancer Institute (NCI).
Summary for Treosulfan
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 174 |
WIPO Patent Applications | 106 |
Japanese Patent Applications | 174 |
Clinical Trial Progress | Phase 3 (2004-08-01) |
Vendors | 35 |
Recent Clinical Trials for Treosulfan
Title | Sponsor | Phase |
---|---|---|
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | Koordinierungszentrum für Klinische Studien - Duesseldorf | Phase 1/Phase 2 |
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | Heinrich-Heine University, Duesseldorf | Phase 1/Phase 2 |
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Treosul® Ideogen) in Myeloma Patients. | University Hospital Inselspital, Berne | Phase 2 |
Clinical Trial Summary for Treosulfan
Top disease conditions for Treosulfan
Top clinical trial sponsors for Treosulfan
US Patents for Treosulfan
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |